2 weeks Ago By ABMN Staff
Cadrenal Therapeutics, Inc. ( NASDAQ:CVKD – Get Free Report ) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 19,400 shares, a growth of 22.
8% from the August 31st total of 15,800 shares. Currently, 3.4% of the company’s shares are sold short.
Based on an average trading volume of 25,600 shares, the short-interest ratio is presently 0.8 days. Analysts Set New Price Targets Separately, HC Wainwright reiterated a “buy” rating and set a $0.
20 target price on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th. Check Out Our Latest Stock Analysis on Cadrenal Therapeutics Cadrenal Therapeutics Trading Down 5.9 % Cadrenal Therapeutics ( NASDAQ:CVKD – Get Free Report ) last released its quarterly earnings data on Wednesday, August 7th.
The company reported ($2.25) earnings per share for the quarter, topping the consensus estimate of ($19.04) by $16.
79. Sell-side analysts predict that Cadrenal Therapeutics will post -6.72 earnings per share for the current year.
About Cadrenal Therapeutics ( Get Free Report ) Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. See Also Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
